HBV enfeksiyonunun tedavisinde CRISPR / Cas9 gen düzenleme sisteminin kullanımı

Abstract

Chronic production of HBV antigens may lead to inflammation and necrosis. This may cause liver enzymes elevation, hepatitis, cirrhosis, hepatocellular carcinoma, and liver failure (Li, et al. 2018). In liver cells, HBV pathogenicity is primarily related to cell-mediated immune response. While HBsAg and HBeAg cause hepatitis and raise of transaminase, HBcAg activates the CD8 response of cytotoxic T lymphocytes and consequently end with liver cells damage. Persistence of chronic hepatitis and cirrhosis causes liver cancer and liver failure (Wooddell, et al. 2013). The initiation of hepatitis and cirrhosis could be successfully inhibited by decreasing serum HBcAg, HBsAg, and HBeAg levels in liver cells (Wooddell, et al. 2013).